Webinar: Recording available [BE/BA News]
Hi Achievwin & all,
The presenters essentially read out what’s on their slides and didn’t provide any background information whatsoever. Since the slides were available for download before, I prepared comments/questions and tried to make them short and as concise as possible.↗️ Wanjie Sun ↗️ Zhen Zhang Interestingly, none of my questions were selected by the moderator. After I posted the second, I received a message “Please post your question only once.” Heck, it was a different one. One which was selected:
❝ Wishful thinking: I hope they give clear direction (kill once for all) - the annoying center/group effect portion for BE studies conducted in one country and in homogenous population.
❝ ❝ FDA is organizing a webinar: A Deep Dive: FDA Draft Guidance on Statistical Approaches to Establishing Bioequivalence
The presenters essentially read out what’s on their slides and didn’t provide any background information whatsoever. Since the slides were available for download before, I prepared comments/questions and tried to make them short and as concise as possible.
- ↗️ Donald Schuirmann
- If \(\small{s_\text{wR}<0.294}\) and hence, ABE has to be assessed, the model is overparameterized in a partial replicate design. Therefore, the software’s optimizer might fail to converge. I suggest to use
FA0(1)
instead ofFA0(2)
in SAS lingo.
- In a meta-study (N ~ 330) we found – as expected – a significant (p <0.05) Group-by-Treatment in ≈5% of studies, i.e., at the false positive rate. If a true G×T is simulated (GMRs 20% apart), it is correctly detected in 34% of cases but not in the 66% others. IMHO, testing for G×T is futile as is any attempt to ‘explain or interpret’ it.
- What is the agency’s definition of an outlier?
How is a Highly Variable Drug defined and is this information available on and within the RLD labeling?
Oh dear, what a waste of time!—
Dif-tor heh smusma 🖖🏼 Довге життя Україна!
Helmut Schütz
The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Dif-tor heh smusma 🖖🏼 Довге життя Україна!
Helmut Schütz
The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Complete thread:
- New guidance on Statistical Approaches to Establishing Bioequivalence Relaxation 2022-12-02 15:53 [BE/BA News]
- A first look Helmut 2022-12-02 16:43
- A first look jag009 2022-12-02 17:58
- A first look BRB 2022-12-02 18:20
- SAS strikes back mittyri 2022-12-02 20:38
- SAS strikes back Helmut 2022-12-02 22:30
- Outliers? mittyri 2022-12-02 22:52
- Outliers? Helmut 2022-12-02 23:11
- SAS strikes back Achievwin 2023-02-07 07:23
- Outliers? mittyri 2022-12-02 22:52
- SAS strikes back Helmut 2022-12-02 22:30
- model-based BE? mittyri 2022-12-07 16:26
- model-based BE? Helmut 2022-12-10 10:13
- Hooker, Moellenhoff et al. are moving MBBE forward mittyri 2023-01-11 15:32
- model-based BE? SMA 2023-01-17 09:41
- model-based BE? Helmut 2022-12-10 10:13
- A first look PharmCat 2022-12-21 19:30
- A first look Rayhope 2023-01-06 06:56
- A first look jag009 2022-12-02 17:58
- Groups, sites… Helmut 2022-12-03 13:09
- SxF ElMaestro 2022-12-04 06:34
- SxF Helmut 2022-12-10 10:37
- New guidance on Statistical Approaches to Establishing Bioequivalence Mahmoud 2022-12-10 14:08
- Webinar: A Deep Dive: FDA Draft Guidance on Statistical Approaches to Establishing Bioequivalence SMA 2023-02-06 09:07
- Webinar: A Deep Dive: FDA Draft Guidance on Statistical Approaches to Establishing Bioequivalence Achievwin 2023-02-07 07:13
- Multi-group studies ad nauseam Helmut 2023-02-07 11:30
- Multi-group studies ad nauseam Achievwin 2023-02-25 16:18
- Webinar: Recording availableHelmut 2023-04-01 10:38
- Multi-group studies ad nauseam Helmut 2023-02-07 11:30
- Speed kills Helmut 2023-02-07 13:02
- Webinar: A Deep Dive: FDA Draft Guidance on Statistical Approaches to Establishing Bioequivalence Achievwin 2023-02-07 07:13
- A first look Helmut 2022-12-02 16:43